Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

GABAergic Drugs for the Treatment of Migraine

Author(s): Anja Puppe and Volker Limmroth

Volume 6, Issue 4, 2007

Page: [247 - 250] Pages: 4

DOI: 10.2174/187152707781387305

Price: $65

Abstract

Within the last decades significant progress has been made in the understanding of the underlying pathophysiological mechanisms of migraine. There is a general agreement now that migraine is not only a vascular phenomenon but also a genetically determined heterogenic ion-channelopathy resulting in cortical-spreading-depression-like events, the temporary impairment of antinociceptive structures of the brainstem and the activation of the trigeminal-vascular system. The development and use of drugs targeting ion-channels and subsequently reducing cortical excitability appears as a promising avenue for both the acute treatment of migraine and migraine prevention. This review summarizes the current knowledge and evidence for GABAergic drugs in the treatment of migraine.

Keywords: GABA transaminase, Topiramate, Valproic acid, Gabapentin, pregabalin


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy